Citius Oncology reported preliminary, unaudited FY2026 fourth-quarter data showing a 120% increase in LYMPHIR (denileukin diftitox-cxdl) unit sales to U.S. wholesalers compared to the prior quarter. The company sold 792 units during the three months ended September 30, 2026, up from 360 units in the fiscal third quarter. Institutional vial orders also rose slightly to 950 vials from 926. As of the report date, 54 institutions have ordered LYMPHIR, an increase from 44 previously reported. The company expects complete results in its December 2026 annual filing. Citius Oncology is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.
